Kornimate/medical-research-clean huggingface dataset:
can protein intake be increased using whole foods post-treatment in cancer patients?

Conditions: Cancer; Other Malnutrition

Summary: cancer and its treatments often result in severe toxicities and side effects that, over the course of treatment, results in weight loss and depletion of key nutrients. loss of muscle mass and strength during cancer treatment is a critical problem because it negatively affects patient response and tolerance to therapy and post-treatment recovery. to restore the nutritional status, it is imperative to stimulate muscle protein anabolism. eggs are high quality protein source, popular and well tolerated by cancer patients. therefore, the objective of this study is to determine whether a nutritional intervention of ≥2 eggs can aid in restoring nutritional status and improving immune function and quality of life of cancer patients' post-treatment. it is an 8- week randomised clinical trial with parallel arm assignment. half of the participants will receive the nutritional intervention (early intervention) and the other half will be on standard of care or usual diet for first 4 weeks. starting from week 5, all participants will receive the nutrition intervention till week 8 (delayed intervention). dietary intake (foods and nutrients), cumulative protein intake (g protein/kg body weight), immunological measures, physical performance and quality of life has been planned to be assessed over time and between groups to evaluate the feasibility of an egg intervention in meeting recommended protein intakes for patients with cancer.


Eligibility criteria:
inclusion criteria: * patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up. * ≥18 years of age * histopathologically confirmed cancer with receipt of a platinum chemotherapy during treatment; active treatment has concluded. * capable of volitional oral semi-solid intake at baseline; able to maintain oral intake over the trial. exclusion criteria: * fed by nasogastric tube, gastrostomy, or total parenteral nutrition * cancer of the brain, cancer of the regions which impact an individual's ability to consume food. * a known hypersensitivity / allergy to eggs. * enrolment in any other clinical protocol or investigational study that may interfere with study procedures. * poorly controlled chronic illnesses or other inflammatory diseases (e.g. chronic obstructive pulmonary disease(copd), uncontrolled non-insulin dependent diabetes, rheumatoid arthritis). * in a clinician opinion, patients who have medical conditions that could interfere with nutrient metabolism or absorption (e.g., short bowel syndrome, crohn's disease, etc.)

Keywords: cancer nutrition protein post-chemotherapy recovery food-related quality of life
evaluate the safety of linaclotide in ibs-c patients in china

Conditions: Irritable Bowel Syndrome-IBS

Summary: this is a multi-center, single arm, observational study to evaluate the safety of linaclotide in ibs-c patients in china. enrolls approximately 3,000 chinese patients from 30 participating sites around china and followed up for half year.

this is a multi-center, one arm, prospective observational study which enrolls approximately 3,000 chinese patients in china.the study will be performed under real world clinical practice setting. patients will be eligible for the study after taking at least one dose of linaclotide. every patient will be followed maximum of 6 months after enrollment. study measures will be collected at baseline and during the follow-up period. incidence of adverse events will be employed to assess the safety and tolerability of linaclotide in chinese patients. the treatment satisfaction will be employed to assess the impact of treatment. the irritable bowel syndrome-quality of life measure (ibs-qol) will be employed to assess the patient's quality of life.

Eligibility criteria:
inclusion criteria: * ≧ 18 years old * provision of subject informed consent prior to any study procedures * has taken at least one dose of linaclotide * not participating in any interventional study currently or during the last 3 months exclusion criteria: * if linaclotide is contraindicated according to the product prescribing information * being unable to comply with study-specified procedure * has ever participated in current study before -

Keywords: ibs
one way to diagnose hepatic insufficiency the first postoperative day after resection: prospective cohort study

Conditions: Indocyanine Green; Postoperative Complications; Acute Liver Failure

Summary: introduction: hepatic insufficiency is a complication that puts the life of the patient undergoing resective surgery at risk. thus, the diagnosis should be made early. the current gold standard allows its diagnosis on the fifth postoperative day. indocyanine green is a water soluble dye. when administered intravenously, it binds to plasma proteins and it is removed unchanged by bile, without experiencing enterohepatic recirculation, which allows estimating the function of hepatocytes and the function of hepato-splacnic flow. there is a measurement system named "non-invasive liver function monitor" (limon®, pulsion medical systems, munich, germany), which allows the measurement of indocyanine green clearance at the patient's bedside. justification: the use of indocyanine green plasma disappearance during the perioperative period tries to know the exact value of the hepatic function in the most real conditions, when the excision has been performed, thus giving the investigators the actual value of the unresected liver. this allows te investigators to estimate the risk of hepatic insufficiency development that can lead to hepatic failure. due to the characteristics of the test, it could get reliable results earlier than the current "gold standard " (50:50 criteria on the 5th postoperative day). hypotheses and objectives: the investigators hypothesized that the determination of the hepatic reserve by identifying the indocyanine plasma clearance in real time after hepatic parenchymal resection could lead to a more accurate and earlier statement of the hepatic reserve than current tests. the aim of the study is to determine the usefulness of indocyanine green in the perioperative period to early diagnosis of hepatic failure. materials and methods: a prospective observational post-authorization study (epa-sp) is performed to study de usefulness of indocyanine green. the study was approved by the ethics and clinical research committee of the university general hospital of ciudad real. surgical patients scheduled for liver surgery, who agreed to be included in the study and signed an informed consent, were included in the study over a two-year period, after having understood the study objectives and its possible complications. measurements were performed with the limon® monitor prior to liver resection and on the first postoperative day to patients undergoing liver resection surgery and compared with gold standard.


Eligibility criteria:
inclusion criteria: * patients susceptible of receiving surgical treatment * liver disease with surgical indication * adulthood * accept inclusion exclusion criteria: * history of hypersensitivity to indocyanine green or iodine * thyroid pathology * underage status * pregnant * irresectable tumors

Keywords: indocyanine green limon postoperative liver failure
sequential chemo-immunotherapy plus thoracic radiotherapy for elderly and/or frail stage iii non-small-cell lung cancer

Conditions: Non-small Cell Lung Cancer Stage III

Summary: concurrent chemoradiotherapy without disease progression followed by consolidation durvalumab is standard of care for unresectable, stage iii non-small-cell lung cancer (nsclc) (the 'pacific regimen'). however, many patients with poor performance status, older age or comorbidities may be ineligible for chemotherapy due to expected high toxicity. the present study aim to investigate the efficacy and toxicities of sequential chemo-immunotherapy plus thoracic radiotherapy for elderly and/or frail stage iii nsclc patients unfit for concurrent chemoradiotherapy, and to identify the optimal thoracic dose for this patient population.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years at time of study entry 2. histologically documented diagnosis of unresectable stage iii nsclc; 3. fully-informed written consent obtained from patients; 4. unfit for concurrent chemoradiotherapy as determined by the multi-disciplinary team board due to one of the following reasons: (1) ecog 2; (2)age≥70;(3) ecog 1 and cci≥1； 5. adequate bone marrow, liver and kidney function 6. life expectancy of at least 3 months 7. at least one measurable (recist 1.1), thoracic lesion that can be irradiated 8. histologic or cytologic confirmation of small cell lung cancer 9. adequate pulmonary function with fev1 \>1 l or \>30 % of predicted value and dlco \>30 % of predicted value exclusion criteria: 1. previous chemo-, immuno- or radiotherapy for nsclc 2. major surgical procedure last 28 days 3. history of allogenic organ transplantation, autoimmune disease, immunodeficiency, hepatitis or hiv 4. uncontrolled intercurrent illness 5. other active malignancy 6. leptomeningeal carcinomatosis 7. immunosuppressive medication 8. pregnant or breastfeeding women

Keywords: thoradic radiotherapy non-small-cell lung cancer chemo-immunotherapy survival
clinical trial on harmonic focus shears

Conditions: Multinodular Goiter

Summary: the purpose of this study is to evaluate the technical benefits, advantages and limits of the use of the harmonic focus curved shears in total thyroidectomy.

according to a randomized sequence, total thyroidectomy was performed in 34 patients using harmonic focus and in 34 patients using clamp-and-tie technique. in this randomized prospective trial, differences in the duration of surgery, intraoperative bleeding and post-operative complications were analysed.

Eligibility criteria:
inclusion criteria: * total thyroidectomy for multinodular goiter in adults patients exclusion criteria: * redo surgery, malignancy.

Keywords: goiter
the acute effect of egg-based high protein meal on hypertensive response to exercise

Conditions: Blood Pressure; Cardiovascular Risk Factor

Summary: the primary purpose of this study is to explore the effect of high versus normal egg-based protein meals on acute exercise-induced elevated blood pressure.

this study is designed to assess bp changes during and post- exercise after consumption of a test breakfast. the design consists of three visits. the first visit will assess each participants aerobic exercise capacity (vo2 max). visit 2 and 3 will be clinical testing days where the subject will consume either the 13g or 30g protein breakfast in a randomized cross-over manner and perform the exercise intervention. bp changes will be monitored before and after breakfast consumption, during the exercise intervention,

Eligibility criteria:
inclusion criteria: * pre-hypertensive (systolic, 120-139 mm hg; diastolic, 80-89 mm hg * age ≥ 21 * body weight \<300 lb (136 kg) * bmi between 20 and 34.9 kg/m2 * fasting plasma glucose \<6.1 mmol/l, * total cholesterol \<6.7 mmol/l * ldl cholesterol \<4.1 mmol/l * tg \<4.5 mmol/l * no pre-existing or history of cardiovascular, renal or liver disease * not currently or previously (past 6 mo) consuming a weight-loss diet or other special/non-balanced diets * no weight loss/gain (±4.5 kg) within the past 6 mo * no physical impairments preventing properly exercise execution * no caffeine intake the day of testing exclusion criteria: * hypertensive * body weight ≥ 300 lb * bmi \ 35 kg/m2 * pregnant or planning pregnancy * unwilling to consume study foods and beverages * fasting plasma glucose ≥6.1 mmol/l * total cholesterol ≥6.7 mmol/l * ldl cholesterol ≥4.1 mmol/l * tg ≥4.5 mmol/l * acute illness * smoking * diabetic * pre-existing or history of cardiovascular, renal or liver disease * currently or previously (past 6 mo) consuming a weight-loss diet or other special/non-balanced diets * weight loss/gain (±4.5 kg) within the past 6 months * physical impairments preventing properly exercise execution * caffeine the day of testing
cognitive control training for remitted depressed patients

Conditions: Major Depression in Remission

Summary: the purpose of this study is to explore the effectiveness of an internet-delivered cognitive control training as a preventive intervention for remitted depressed patients.

prospective studies have linked impaired cognitive control to increased cognitive vulnerability for future depression. importantly, experimental studies indicate that cognitive control training can be used to reduce rumination and depressive symptomatology in mdd samples. furthermore, studies exploring the potential of cognitive control training in at-risk undergraduate students indicate that cognitive control training has beneficial effects on rumination, an important vulnerability factor for depression. provided that remitted depressed patients form a high-risk group for developing future depressive episodes, the current study will explore whether internet-delivered cognitive control training can be used to reduce vulnerability for future depression in remitted depressed patients. the investigators will explore effects on depressive symptomatology, (mal-)adaptive emotion regulation (directly following training and at 3 months follow-up), and indices of functioning (at 3 months follow-up).

Eligibility criteria:
inclusion criteria: * history of ≥ 1 depressive episode(s) * currently in stable full or partial remission (≥ 6 months) exclusion criteria: * major depressive disorder (mdd; current) * bipolar disorder (current and/or previous) * psychotic disorder (current and/or previous) * neurological impairments (current and/or previous) * excessive substance abuse (current and/or previous) * no other comorbid disorders (current) * no ongoing psychotherapeutic treatment (maintenance treatment is allowed, but with a frequency less than once / 3 weeks) * use of antidepressant medication is allowed if kept at a constant level
an internet delivered intervention for re-adjustment to sexual intimacy with an ostomy after cancer

Conditions: Colorectal Cancer; Sexual Dysfunction

Summary: this study investigates the feasibility and efficacy of an internet-delivered intervention for the sexual and intimate re-adjustment of couples in which one partner is living with a temporary or permanent ostomy (e.g., colostomy, ileostomy, urostomy) following treatment for colorectal and/or bladder cancer. the two session intervention will be delivered via online videoconferencing and will focus on facilitating couples' communication around their sexual and intimate relationship. exercises from sex therapy will be used to scaffold conversations about motivations for having sex, intimacy and sensual pleasure, and relational strengths for coping. the intervention aims to enhance couples' ability to cope with the changes in their sexual and intimate relationship. a group of couples receiving written educational material only will be used as a comparison group to measure change in sexual and intimate adjustment over time.


Eligibility criteria:
inclusion criteria: patients meeting all of the following criteria will be eligible for the study: * patients who have had a diagnosis of colorectal and/or bladder cancer within their lifetime * patients who are at least 1-month post active treatment for colorectal and/or bladder cancer * patients who have an ostomy due to colorectal and/or bladder cancer (e.g., colostomy, ileostomy, urostomy; permanent or temporary) * patients who are in a committed intimate relationship * patients who report changes in their sexual/intimate relationship associated with colorectal and/or bladder cancer and/or living with an ostomy * patients who have access to the internet in a private space * patients who reside in ontario * patients who are 18 years of age or older or partners of patients who meet the above criteria and who are 18 years of age or older exclusion criteria: patients/couples will be excluded from study participation if: * patient is undergoing active treatment for cancer * patient or partner report high levels of relational distress and would be better suited to couples therapy * couple is attending or plans to attend couples or sex therapy concurrently with participation in study * patient or partner is currently experiencing mental health concerns that would interfere with study participation (e.g., suicidal ideation, psychotic disorders, substance abuse, spousal abuse) * patient or partner lack english proficiency
identifying the needs of operation enduring freedom/operation iraqi freedom (oef/oif) veterans and their families: tbi and co-occurring behavioral health issues

Conditions: Traumatic Brain Injury; Co-Occurring Behavioral Health Issues

Summary: the purpose of this study is to explore and potentially increase the capacity of the non-va community mental health system within the state of colorado to provide a comprehensive and coordinated service delivery system for operation enduring freedom (oef)/operation iraqi freedom (oif) veterans and their families. the specific population of interest is oef/oif veterans with a history of traumatic brain injury (tbi) and co-occurring behavioral health issues.

the focus of this project is on qualitative data collection to facilitate product development including assessment and treatment guidelines to improve non-va community mental health care for oef/oif veterans with tbi and co-occurring behavioral health issues within the state of colorado. in addition to the development of assessment and treatment guidelines, other products developed through this study will include a training and accompanying toolkit, which may be used for annual educational training of mental health providers. as such, there are no hypotheses associated with this study. this statewide initiative may not only improve quality and access to non-va community mental health care for persons with tbi and co-occurring behavioral health issues within colorado, but also serve as a model for implementation across the country.

Eligibility criteria:
inclusion criteria: * colorado behavioral health organization (bho) mental health providers * oef/oif united states veterans * family members and/or friends of oef/oif united states veterans * ages 18-65 exclusion criteria: - n/a

Keywords: oef/oif veterans traumatic brain injury community mental health
carotid plaque burden in patients with philadelphia negative myeloproliferative neoplasms

Conditions: Myeloproliferative Neoplasm

Summary: in around 90% of the patients with mpns, an acquired mutation that promotes jak/stat signaling is identified \[3, 4\]. the jak/stat pathway transduces signals from cytokines including erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor.24 a point mutation that activates jak2, jak2v617f, is present in around 95% of patients with pv and 40% to 60% of patients with et and mf

all patients will be subjected to a thorough assessment of history, complete clinical examination, and investigations as complete blood picture including neutrophil-lymphocyte ratio which will be analyzed with automated blood count analyzers, serum uric acid, serum creatinine and lipid profile. all patients will undergo carotid imaging using colour doppler ultrasonography for assessment of carotid plaque burden. the control group will undergo carotid ultrasonography who will be recruited among apparently healthy volunteers aiming to match the patient group regarding age, sex and classical risk factors for atherosclerosis as arterial hypertension, hyperlipidemia, diabetes, smoking or obesity.

Eligibility criteria:
inclusion criteria: * all patients aged 18 years and older who were newly diagnosed to have philadelphia negative myeloproliferative neoplasms between september 2014 and november 2022 at sohag university hospital, department of internal medicine, hematology unit and hematology outpatient clinic. exclusion criteria: * patients were excluded if: (1) their disease of thrombocytosis or polycythemia was determined to be reactive, (2) their disease was not newly diagnosed, (3) their disease met who criteria for chronic or acute myeloid leukemia.
docetaxel alone or in combination with enzalutamide for mcrpc previously treated with abiraterone at mhspc stage

Conditions: Prostate Cancer; Castrate Resistant Prostate Cancer

Summary: new androgen pathway targeting agents (arta), including abiraterone acetate, apalutamide and enzalutamide, are approved and used in treatment of metastatic hormonal sensitive prostate cancer(mhspc). however, the development of castration-resistance prostate cancer(crpc) is only a matter of time. the use of sequential artas in mcrpc showed limited benefit in retrospective series and prospective trials. therefore this sequence should be avoided because of known cross resistance and the availability of chemotherapy and poly adenosine diphosphate-ribose polymerase(parp) inhibitors (if a relevant mutation is present). recently, a randomized controlled trial(rct), the abido-sogug, indicated that compared with docetaxel, maintaining abiraterone added to docetaxel in chemotherapy-naive patients who have experienced cancer progression to abiraterone treatment could not improve radiographic progression-free survival or the other endpoints.however, another rct, the preside trial, indicated that in patients who had progressed on enzalutamide, continued enzalutamide treatment in combination with docetaxel led to a significant improvement of pfs compared with placebo plus docetaxel. the aims of this trial is to assess both the efficacy and safety of docetaxel in combination with enzalutamide as first-line treatment in mcrpc patients progressed on abiraterone.


Eligibility criteria:
inclusion criteria: * adenocarcinoma * mcrpc * eastern cooperative oncology group(ecog) 0-1 * prior abiraterone treatment exclusion criteria: * prior enzalutamide or docetaxel treatment

Keywords: chemotherapy enzalutamide abiraterone
glider ptca balloon catheter registry

Conditions: Coronary Disease

Summary: the objective of this registry is to demonstrate the utility of the glider ptca balloon catheter for crossing during the treatment of coronary artery disease.


Eligibility criteria:
inclusion criteria: * patients undergoing pci who are at least 18 years old * pci procedure included the use of at least one glider ptca balloon catheter * patient has been informed, in accordance with local requirements, that their data will be used in the glider registry exclusion criteria: * n/a